{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:24:12Z","timestamp":1785939852255,"version":"3.56.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K99DA043011"],"award-info":[{"award-number":["K99DA043011"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA034086"],"award-info":[{"award-number":["R01DA034086"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Albert Einstein College of Medicine Liver Research Center","award":["P30DK41296"],"award-info":[{"award-number":["P30DK41296"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Direct-acting antiviral (DAA) therapy is highly effective in people who inject drugs (PWID); however, rates, specific injection behaviors, and social determinants associated with hepatitis C virus (HCV) reinfection following DAA therapy among PWID on opioid agonist therapy (OAT) are poorly understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PREVAIL was a randomized controlled trial that assessed models of HCV care for 150 PWID on OAT. Those who achieved sustained virologic response (SVR) (n = 141; 94%) were eligible for this extension study. Interviews and assessments of recurrent HCV viremia occurred at 6-month intervals for up to 24 months following PREVAIL. We used survival analysis to analyze variables associated with time to reinfection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 141 who achieved SVR, 114 had a least 1 visit in the extension study (62% male; mean age, 52 years). Injection drug use (IDU) was reported by 19% (n = 22) in the extension study. HCV reinfection was observed in 3 participants. Over 246 person-years of follow-up, the incidence of reinfection was 1.22\/100 person-years (95% CI, 0.25\u20133.57). All reinfections occurred among participants reporting ongoing IDU. The incidence of reinfection in participants reporting ongoing IDU (41 person-years of follow-up) was 7.4\/100 person-years (95% CI, 1.5\u201321.6). Reinfection was associated with reporting ongoing IDU in the follow-up period (P &amp;lt; .001), a lack confidence in the ability to avoid contracting HCV (P &amp;lt; .001), homelessness (P = .002), and living with a PWID (P = .007).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>HCV reinfection was low overall, but more common among people with ongoing IDU following DAA therapy on OAT, as well as those who were not confident in the ability to avoid contracting HCV, homeless, or living with a PWID. Interventions to mediate these risk factors following HCV therapy are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz693","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T11:25:44Z","timestamp":1563967544000},"page":"2695-2702","source":"Crossref","is-referenced-by-count":55,"title":["Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy"],"prefix":"10.1093","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-3083","authenticated-orcid":false,"given":"Matthew J","family":"Akiyama","sequence":"first","affiliation":[{"name":"Divisions of General Internal Medicine, Bronx, New York"},{"name":"Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lipsey","sequence":"additional","affiliation":[{"name":"Divisions of General Internal Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonseong","family":"Heo","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, College of Behavioral, Social, and Health Sciences, Clemson University, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Agyemang","sequence":"additional","affiliation":[{"name":"Divisions of General Internal Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna L","family":"Norton","sequence":"additional","affiliation":[{"name":"Divisions of General Internal Medicine, Bronx, New York"},{"name":"Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"Divisions of General Internal Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara","family":"Lora","sequence":"additional","affiliation":[{"name":"Divisions of General Internal Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H","family":"Litwin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of South Carolina School of Medicine\u2013Greenville, Greenville"},{"name":"Department of Medicine, Prisma Health-Upstate, Greenville"},{"name":"Clemson University School of Health Research, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"2020082914220743000_CIT0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/liv.13949","article-title":"Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework","volume":"39","author":"Day","year":"2019","journal-title":"Liver Int"},{"key":"2020082914220743000_CIT0002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S2468-1253(17)30404-1","article-title":"Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicen","volume":"3","author":"Grebely","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2020082914220743000_CIT0003","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"key":"2020082914220743000_CIT0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020082914220743000_CIT0005","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users","volume":"174","author":"Tsui","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2020082914220743000_CIT0006","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/add.12682","article-title":"The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users","volume":"109","author":"Nolan","year":"2014","journal-title":"Addiction"},{"key":"2020082914220743000_CIT0007","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","article-title":"Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort","volume":"69","author":"Rossi","year":"2018","journal-title":"J Hepatol"},{"key":"2020082914220743000_CIT0008","author":"Alderks","year":"2017"},{"key":"2020082914220743000_CIT0009","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"2020082914220743000_CIT0010","article-title":"Intensive models of hepatitis C care for people who inject drugs engaged in opioid agonist therapy","author":"Akiyama","journal-title":"Ann Intern Med"},{"key":"2020082914220743000_CIT0011","author":"Centers for Disease Control and Prevention"},{"key":"2020082914220743000_CIT0012","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cld.2006.08.012","article-title":"Hepatitis C virus and liver transplantation","volume":"10","author":"Verna","year":"2006","journal-title":"Clin Liver Dis"},{"key":"2020082914220743000_CIT0013","volume-title":"Combating the silent epidemic of viral hepatitis (action plan for the prevention, care, and treatment of viral hepatitis)","author":"US Department of Health and Human Services","year":"2011"},{"key":"2020082914220743000_CIT0014","doi-asserted-by":"crossref","first-page":"271","DOI":"10.7326\/0003-4819-156-4-201202210-00004","article-title":"The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007","volume":"156","author":"Ly","year":"2012","journal-title":"Ann Intern Med"},{"key":"2020082914220743000_CIT0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.dld.2010.05.006","article-title":"Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States","volume":"43","author":"Rein","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"513\u201321","key":"2020082914220743000_CIT0016","first-page":"521.e1","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"2020082914220743000_CIT0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.12576","article-title":"Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis","volume":"35","author":"Akhtar","year":"2015","journal-title":"Liver Int"},{"key":"2020082914220743000_CIT0018","volume-title":"Significant and sustained improvement of Health-Related Quality of Life (HRQL) scores in patients with hepatitis C (HCV) and sustained virologic response (SVR)","author":"Younossi","year":"2017"},{"key":"2020082914220743000_CIT0019","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C aft","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"2020082914220743000_CIT0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12879-018-2964-5","article-title":"Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy","volume":"18","author":"Akiyama","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2020082914220743000_CIT0021","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2020082914220743000_CIT0022","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2017","journal-title":"J Viral Hepat"},{"key":"2020082914220743000_CIT0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jvh.12859","article-title":"Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era","volume":"25","author":"Falade-Nwulia","year":"2018","journal-title":"J Viral Hepat"},{"key":"2020082914220743000_CIT0024","volume-title":"Hepatitis C virus reinfection and injecting risk behavior following elbasvir\/grazoprevir treatment in participants on opiate agonist therapy: C-EDGE Co-Star Part B","author":"Dore","year":"2017"},{"key":"2020082914220743000_CIT0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(18)32277-3","article-title":"Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model","volume":"393","author":"Heffernan","year":"2019","journal-title":"Lancet"},{"key":"2020082914220743000_CIT0026","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2013.03.008","article-title":"Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C","volume":"59","author":"Marco","year":"2013","journal-title":"J Hepatol"},{"key":"2020082914220743000_CIT0027","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1017\/S095026880900212X","article-title":"Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size","volume":"137","author":"Craine","year":"2009","journal-title":"Epidemiol Infect"},{"key":"2020082914220743000_CIT0028","doi-asserted-by":"crossref","first-page":"e0177341","DOI":"10.1371\/journal.pone.0177341","article-title":"Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: implications for prevention","volume":"12","author":"Eckhardt","year":"2017","journal-title":"PLoS One"},{"key":"2020082914220743000_CIT0029","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12889-017-4102-5","article-title":"HCV screening in a cohort of HIV infected and uninfected homeless and marginally housed women in San Francisco, California","volume":"17","author":"Page","year":"2017","journal-title":"BMC Public Health"},{"key":"2020082914220743000_CIT0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/cid\/cix295","article-title":"Prevalence of Human immunodeficiency virus, hepatitis C virus, and hepatitis B virus among homeless and nonhomeless United States veterans","volume":"65","author":"Noska","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020082914220743000_CIT0031","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1186\/1471-2458-12-1058","article-title":"Frequent food insecurity among injection drug users: correlates and concerns","volume":"12","author":"Strike","year":"2012","journal-title":"BMC Public Health"},{"key":"2020082914220743000_CIT0032","first-page":"pii","article-title":"Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C","author":"Geddes","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020082914220743000_CIT0033","first-page":"pii","article-title":"Changing dynamics of the drug o","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"key":"2020082914220743000_CIT0034","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugalcdep.2010.11.025","article-title":"Correlates of risky injection practices among past-year injection drug users among the US general population","volume":"116","author":"Ropelewski","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"2020082914220743000_CIT0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s10461-008-9359-3","article-title":"Stimulant injectors in Ukraine: the next wave of the epidemic?","volume":"12","author":"Booth","year":"2008","journal-title":"AIDS Behav"},{"key":"2020082914220743000_CIT0036","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1093\/infdis\/jir535","article-title":"Inactivation and survival of hepatitis C virus on inanimate surfaces","volume":"204","author":"Doerrbecker","year":"2011","journal-title":"J Infect Dis"},{"key":"2020082914220743000_CIT0037","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/infdis\/jix427","article-title":"Recovery of infectious hepatitis C virus from injection paraphernalia: implications for prevention programs serving people who inject drugs","volume":"217","author":"Heimer","year":"2018","journal-title":"J Infect Dis"},{"key":"2020082914220743000_CIT0038","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz693\/30693156\/ciz693.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/12\/2695\/33698052\/ciz693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/12\/2695\/33698052\/ciz693.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T17:24:39Z","timestamp":1598894679000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/12\/2695\/5538954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,7,26]]},"published-print":{"date-parts":[[2020,6,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz693","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,15]]},"published":{"date-parts":[[2019,7,26]]}}}